Swiss pharma giant Roche (SIX: ROG) has announced positive data from the Phase III lidERA Breast Cancer study of giredestrant ...

The bipolar disorder market across the USA, Europe, and Japan is forecast to rise from $5.6 billion in 2024 to $9.4 billion ...

German biotech Disco Pharmaceuticals has appointed Mark Manfredi as chief executive and closed a 36 million euro ($39 million ...

For decades, the generics industry has been dedicated to supporting the financial sustainability of health systems. By ...

Hong Kong-based Ascletis Pharma has announced that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, ...

The diagnosed prevalent cases of diabetic macular edema (DME) in the diabetes population across the seven major markets (7MM: ...

Diakonos Oncology has received more than $7 million from the Cancer Prevention and Research Institute of Texas to support a ...

PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics (Nasdaq: MCRB) chief executive Eric ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines ...

The UK government has announced that the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded ...

US healthcare giant Johnson & Johnson has announced new data from the investigational Phase III MajesTEC-3 study showing the ...